Mersana $MRSN and the FDA have come up with a newly revised development program for the biotech’s lead drug just a couple months after a patient’s death triggered a partial hold on enrolling more people for the study.
From the beginning, Mersana noted that the death may have been caused by XMT-1522, an antibody drug conjugate designed to drop a therapeutic payload on HER2-expressing tumors.
Quickly navigating their way through the challenge, the company came up with a plan to exclude any patient candidates with advanced hepatic impairment. Researchers are also adding a once-every-four-weeks dose regimen to compared the efficacy and safety responses in patients.
The Cambridge, MA-based biotech has kept its other clinical program on track for XMT-1536 — targeting NaPi2b — but execs say they’ll make similar changes on the parallel track. And after initially boosting the biotech’s share price, investors scrambled, sending shares down 25% Monday afternoon.
Mersana CEO Anna Protopapas saw her company’s stock take a nasty hit on the news of the partial hold earlier. Since then, the share price has been rising steadily — until today’s news came through.
This morning the stock jumped about 8% in pre-market trading to help complete the comeback, then plunged, dropping into the red by about 25% in an abrupt turnabout.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,900+ biopharma pros who read Endpoints News by email every day.Free Subscription